Interferon alfa-2a shows both antiviral and antitumoral activity, but
its role in the treatment of many conditions remains controversial. It
is, however, the treatment of choice for chronic, active hepatitis B,
chronic hepatitis C and AIDS-related Kaposi's sarcoma, and is also ef
fective in metastatic renal carcinoma and chronic myelogenous leukaemi
a. Optimal dose regimens are unclear, and further randomized trials ar
e needed.